Indian drug Price Fixing Moves
With the Indian cabinet approving the setting-up of the national Pharmaceutical Pricing Authority, the process to speed up price-fixing for drugs based on data provided by the manufacturers has moved closer.
The NPPA, proposed in the Drug (Price Control) Order of 1994, is expected to start functioning in March, and until then the Department of Chemicals and Fertilizers is likely to put on hold any decisions regarding decontrol of drugs. The Department has received 30 applications from companies seeking decontrol of 19 drugs since the DPCO was announced.
Duty Changes Recommended Meantime, in its pre-budget recommendations, the Department of Chemicals and Petrochemicals is seeking the abolition of duty on imports of nine intermediates used in the manufacture of bulk drugs. Among the products recommended for duty-free imports are pancreas used in insulin manufacture, D-2 aminobutanol, L-2 aminobutanol and 3-4 xylindine (an ingredient in vitamin B2 tablets).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze